An unusual association in a patient with COVID-19-related ARDS and bilateral pleural effusion

Auteurs-es

  • Antonio Cipolla Pneumologia, Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Catania; Pneumologia, Dipartimento di Scienze Biomediche, Odontoiatriche e delle Immagini Morfologiche e Funzionali (BIOMORF), Università degli Studi di Messina
  • Antonio Faiello Pneumologia, Dipartimento di Scienze Biomediche, Odontoiatriche e delle Immagini Morfologiche e Funzionali (BIOMORF), Università degli Studi di Messina
  • Giuseppe Ielo Pneumologia, Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Catania; Pneumologia, Dipartimento di Scienze Biomediche, Odontoiatriche e delle Immagini Morfologiche e Funzionali (BIOMORF), Università degli Studi di Messina
  • Giorgio Morana Pneumologia, Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Catania; Pneumologia, Dipartimento di Scienze Biomediche, Odontoiatriche e delle Immagini Morfologiche e Funzionali (BIOMORF), Università degli Studi di Messina
  • Federica Lo Bello Pneumologia, Dipartimento di Scienze Biomediche, Odontoiatriche e delle Immagini Morfologiche e Funzionali (BIOMORF), Università degli Studi di Messina
  • Alfio Proietto Pneumologia, Dipartimento di Scienze Biomediche, Odontoiatriche e delle Immagini Morfologiche e Funzionali (BIOMORF), Università degli Studi di Messina
  • Carlo Vanchieri Pneumologia, Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Catania
  • Gaetano Caramori Pneumologia, Dipartimento di Scienze Biomediche, Odontoiatriche e delle Immagini Morfologiche e Funzionali (BIOMORF), Università degli Studi di Messina

DOI :

https://doi.org/10.13129/1828-6550/APMB.111.1.2023.CCS1

Mots-clés :

acute respiratory failure, sarcoidosis, pleural effusion, pneumonia

Résumé

We present the case of a 76-year-old female, previously diagnosed with pulmonary sarcoidosis, that was admitted to our Unit of Pulmonology for acute hypoxemic respiratory failure secondary to COVID-19-related acute respiratory distress syndrome (ARDS) and with bilateral pleural effusions. Despite the therapy the patient’s conditions gradually deteriorated during the hospital stay with progressive hypoxemia and the patient died 36 days after the admission

Références

References

1. Baughman, R.P., Lower, E.E. (2021). COVID-19 infections in sarcoidosis: a prospective single center study of 886 sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis. 38(2), e2021029. doi: 10.36141/svdld.v38i2.11646.

2. Ji, X., Lu, J., Zuo, A., Sun, F., Peng, H., Lu, D. (2022) Pleural involvements in pulmonary sarcoidosis: A case report and review of the literature. Front. Med.(9), 902711. doi: 10.3389/fmed.2022.902711.

3. Chong, W.H., Saha, B.K., Conuel, E., Chopra, A. (2021). The incidence of pleural effusion in COVID-19 pneumonia: State-of-the-art review. Heart Lung. 50(4), 481-490. doi: 10.1016/j.hrtlng.2021.02.015.

4. Rathore, S.S., Hussain, N., Manju, A.H., Wen, Q., Tousif, S., Avendaño-Capriles, C.A., Hernandez-Woodbine, M.J., Rojas, G.A., Vatsavayi, P., Tera, C.R., Ali, M.A., Singh, R., Saleemi, S., Patel, D.M. (2022). Prevalence and clinical outcomes of pleural effusion in COVID-19 patients: A systematic review and meta-analysis. J Med Virol.94(1), 229-239. doi: 10.1002/jmv.27301.

5. Duong, H.T., Bonham, C.A. (2018). Sarcoidosis-associated pulmonary hypertension: pathophysiology, diagnosis and treatment. ClinPulm Med. 25(2),52-60.doi:10.1097/CPM.0000000000000252

6. Mirsaeidi, M., Omar, H.R., Baughman, R., Machado, R., Sweiss, N. (2016). The association between BNP, 6MWD test, DLCO% and pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis.33(4),317-320.

7. Ichinose, A., Otani, H., Oikawa, M., Takase, K., Saito, H., Shimokawa, H., Takahashi, S. (2008). MRI of cardiac sarcoidosis: basal and subepicardial localization of myocardial lesions and their effect on left ventricular function. AJR Am J Roentgenol. 191(3),862-9. doi: 10.2214/AJR.07.3089.

8. Kiko, T., Yoshihisa, A., Kanno, Y., Yokokawa, T., Abe, S., Miyata-Tatsumi, M., Misaka, T., Oikawa, M., Kobayashi, A., Ishida, T., Takeishi, Y. (2018). A Multiple Biomarker Approach in Patients with Cardiac Sarcoidosis. Int Heart J.59(5),996-1001. doi: 10.1536/ihj.17-695.

9. Darlington, P., Gabrielsen, A., Cederlund, K., Kullberg, S., Grunewald, J., Eklund, A., Sörensson P. (2019). Diagnostic approach for cardiac involvement in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 36(1),11-17. doi: 10.36141/svdld.v36i1.7132.

10. Dökümcü, E. (2021). The role of carbohydrate antigen 125 in COVID-19. Med Hypotheses.151:110590. doi: 10.1016/j.mehy.2021.110590.

11. Ros-Lucas, J.A., Pascual-Figal, D.A., Noguera-Velasco, J.A., Hernández-Vicente, Á., Cebreiros-López, I., Arnaldos-Carrillo, M., Martínez-Ardil, I.M., García-Vázquez, E., Aparicio-Vicente, M., Solana-Martínez, E., Ruiz-Martínez, S.Y., Fernández-Mula, L., Andujar-Espinosa, R., Fernández-Suarez, B., Sánchez-Caro, M.D., Peñalver-Mellado, C., Ruiz-López, F.J. (2022). CA 15-3 prognostic biomarker in SARS-CoV-2 pneumonia. Sci Rep.(1):6738. doi: 10.1038/s41598-022-10726-7.

12.Kalluri, M., Judson, M.A. (2007). Sarcoidosis associated with an elevated serum CA 125 level: description of a case and a review of the literature. Am J Med Sci. 334(6):441-3. doi: 10.1097/MAJ.0b013e3180f60bc4.

13. Türk, Y., Shapiro, C., Braunstahl, G.J. (2017). CA 15.3: a marker of disease activity in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 34(1):100-101. doi: 10.36141/svdld.v34i1.4786.

14. Sharma, O.P.(2000). Hypercalcemia in granulomatous disorders: a clinical review. Curr Opin Pulm Med.6(5),442-7. doi: 10.1097/00063198-200009000-00010.

15. Baughman, R.P., Janovcik, J., Ray, M., Sweiss, N., Lower, E.E.(2013). Calcium and vitamin D metabolism in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 30(2), pp. 113-120

Téléchargements

Publié

2023-04-07

Numéro

Vol. 111 No. 1 (2023)

Rubrique

CLINICAL CASE SEMINAR

Licence

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:
  • Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  • Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).